{"session_id": 20, "bill_id": 5538, "bill_type": "House Bill", "bill_number": 1024, "bill_title": "place certain substances on the controlled substances schedule and to declare an emergency.", "sponsors": [], "keywords": ["Controlled Substances", "Public Safety"], "audio": [{"meeting_datetime": "2014-01-21T00:00:00-06:00", "committee": "HHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/hhe05.mp3", "start_seconds": 142.0}, {"meeting_datetime": "2014-01-21T00:00:00-06:00", "committee": "HHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/hhe05.mp3", "start_seconds": 142.0}, {"meeting_datetime": "2014-01-21T00:00:00-06:00", "committee": "HHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/hhe05.mp3", "start_seconds": 142.0}, {"meeting_datetime": "2014-01-22T00:00:00-06:00", "committee": "HOU", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/hou06.mp3", "start_seconds": 1318.0}, {"meeting_datetime": "2014-01-22T00:00:00-06:00", "committee": "HOU", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/hou06.mp3", "start_seconds": 1318.0}, {"meeting_datetime": "2014-01-22T00:00:00-06:00", "committee": "HOU", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/hou06.mp3", "start_seconds": 1318.0}, {"meeting_datetime": "2014-01-29T00:00:00-06:00", "committee": "SHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/she10.mp3", "start_seconds": 645.0}, {"meeting_datetime": "2014-01-29T00:00:00-06:00", "committee": "SHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/she10.mp3", "start_seconds": 645.0}, {"meeting_datetime": "2014-01-29T00:00:00-06:00", "committee": "SHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/she10.mp3", "start_seconds": 645.0}, {"meeting_datetime": "2014-01-29T00:00:00-06:00", "committee": "SHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/she10.mp3", "start_seconds": 645.0}, {"meeting_datetime": "2014-02-04T00:00:00-06:00", "committee": "SEN", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/sen13.mp3", "start_seconds": 5140.0}, {"meeting_datetime": "2014-02-04T00:00:00-06:00", "committee": "SEN", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/sen13.mp3", "start_seconds": 5140.0}, {"meeting_datetime": "2014-02-04T00:00:00-06:00", "committee": "SEN", "url": "https://sdpb.sd.gov/sdpbpodcast/2014/sen13.mp3", "start_seconds": 5140.0}], "bill_versions": [{"bill_id": 5538, "bill_version_id": 28331, "bill_version": "Introduced", "bill_version_date": "2014-01-09T15:32:55.293-06:00", "bill_text": "FOR AN ACT ENTITLED, An Act to place certain substances on the controlled substances schedule and to declare an emergency. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF SOUTH DAKOTA: Section 1. That \u00a7 34-20B-14 be amended to read as follows: 34-20B-14. Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in Schedule I, unless specifically excepted, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Bufotenine; (2) Diethyltryptamine (DET); (3) Dimethyltryptamine (DMT); (4) 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT); (5) 5-methoxy-3, 4-methylenedioxy amphetamine; (6) 4-bromo-2, 5-dimethoxyamphetamine; (7) 4-methoxyamphetamine; (8) 4-methoxymethamphetamine; (9) 4-methyl-2, 5-dimethoxyamphetamine; (10) Hashish and hash oil; (11) Ibogaine; (12) Lysergic acid diethylamide; (13) Mescaline; (14) N-ethyl-3-piperidyl benzilate; (15) N-methyl-3-piperidyl benzilate; (16) 1-(-(2-thienyl)cyclohexyl) piperdine piperidine (TCP); (17) Peyote, except that when used as a sacramental in services of the Native American church in a natural state which is unaltered except for drying or curing and cutting or slicing, it is hereby excepted.; (18) Psilocybin; (19) Psilocyn; (20) Tetrahydrocannabinol, other than that which occurs in marijuana in its natural and unaltered state, including any compound, except nabilone or compounds listed under a different schedule, structurally derived from 6,6. dimethyl-benzo[c]chromene by substitution at the 3-position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl groups, whether or not the compound is further modified in any of the following ways: (a) By partial to complete saturation of the C-ring; or (b) By substitution at the 1-position with a hydroxyl or methoxy group; or (c) By substitution at the 9-position with a hydroxyl, methyl, or methylhydoxyl group; or (d) By modification of the possible 3-alkyl group with a 1,1. dimethyl moiety, a 1,1. cyclic moiety, an internal methylene group, an internal acetylene group, or a terminal halide, cyano, azido, or dimethylcarboxamido group. Some trade and other names: JWH-051; JWH-057; JWH-133; JWH-359; HHC; AM-087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211; HU-243; HU-336; (21) 3, 4, 5-trimethoxy amphetamine; (22) 3, 4-methylenedioxy amphetamine; (23) 3-methoxyamphetamine; (24) 2, 5-dimethoxyamphetamine; (25) 2-methoxyamphetamine; (26) 2-methoxymethamphetamine; (27) 3-methoxymethamphetamine; (28) Phencyclidine; (29) 3, 4-methylenedioxymethamphetamine (MDMA); (30) 3, 4-methylenedioxy-N-ethylamphetamine; (31) N-hydroxy-3, 4-methylenedioxyamphetamine; (32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline); (33) 2,5 Dimethoxy-4-ethylamphetamine; (34) N,N-Dimethylamphetamine; (35) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; (36) Aminorex; (37) Cathinone and other variations, defined as any compound, material, mixture, preparation or other product unless listed in another schedule or an approved FDA drug (e.g. buproprion, pyrovalerone), structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways: (a) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substitutents; (b) By substitution at the 3-position with an acyclic alkyl substituent; (c) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a cyclic structure. Some trade or other names: methcathinone, 4-methyl-N-methylcathinone (mephedrone); 3,4-methylenedioxy-N-methylcathinone (methylone); 3,4-methylenedioxypyrovalerone (MDPV); Naphthylpyrovalerone (naphyrone); 4-flouromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk-PMMA); Ethcathinone (N-Ethylcathinone); 3,4-methylenedioxyethcathinone (ethylone); Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N-dimethylcathinone (metamfepramone); Alpha-pyrrolidinopropiophenone (alpha-PPP); 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP); 3,4-methylenedioxyalphapyrrolidinopropiophenone (MDPPP); Alpha-pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4.-Methyl-alpha-pyrrolidinobutiophenone (MPBP); Methyl-.-pyrrolindinopropiophenone (MPPP); Methyl-.-pyrrolidino-hexanophenone (MPHP); Buphedrone; Methyl-N-ethylcathinone; Pentedrone; Dimethylmethcathinone (DMMC); Dimethylethcathinone (DMEC); Methylenedioxymethcathinone (MDMC); Pentylone; Ethylethcathinone; Ethylmethcathinone; Fluoroethcathinone; methyl-alpha-pyrrolidinobutiophenone (MPBP); Methylecathinone (MEC); Methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP); Methoxymethcathinone (MOMC); Methylbuphedrone (MBP); Benzedrone (4-MBC); Dibutylone (DMBDB); Dimethylone (MDDMA); Diethylcathinone; Eutylone (EBDB); N-ethyl-N-Methylcathinone; N-ethylbuphedrone; (38) 2,5-Dimethoxy-4-ethylamphetamine (DOET); (39) Alpha-ethyltryptamine; (40) 4-Bromo-2,5-dimethoxy phenethylamine; (41) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7); (42) 1-(3-trifluoromethylphenyl) piperazine (TFMPP); (43) Alpha-methyltryptamine (AMT); (44) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); (45) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); (46) Synthetic cannabinoids. Any material, compound, mixture, or preparation that is not listed as a controlled substance in another schedule, is not an FDA-approved drug, and contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric), homologues, and salts of isomers and homologues, unless specifically excepted, whenever the existence of these salts, isomers, homologues, and salts of isomers and homologues is possible within the specific chemical designation: (a) Naphthoylindoles. Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinhyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Some trade or other names: JWH-015; 1-pentyl-3-(1-naphthoyl)indole (JWH-018); 1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398; 1-pentyl-3-(1-naphthoyl)indole (AM-678); 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201); WIN 55-212; JWH-004; JWH-007; JWH-009; JWH-011; JWH-016; JWH-020; JWH-022; JWH-046; JWH-047; JWH-048; JWH-049; JWH-050; JWH-070; JWH-071; JWH_072; JWH-076; JWH-079; JWH-080; JWH-082; JWH-094; JWH-096; JWH-098; JWH-116; JWH-120; JWH-148; JWH-149; JWH-164; JWH-166; JWH-180; JWH-181; JWH-182; JWH-189; JWH-193; JWH-198; JWH-211; JWH-212; JWH-213; JWH-234; JWH-235; JWH-236; JWH-239; JWH-240; JWH-241; JWH-258; JWH-262; JWH-386; JWH-387; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400; JWH-412; JWH-413; JWH-414; JWH-415; JWH-424; AM-678; AM-1220; AM-1221; AM-1235; AM-2232; (b) Naphthylmethylindoles. Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N- methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Some trade or other names: JWH-175; JWH-184; JWH-185; JWH-192; JWH-194; JWH-195; JWH-196; JWH-197; JWH-199; (c) Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Some trade or other names: 1-cyc lohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18); 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8); 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250); 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203); JWH-167; JWH-201; JWH-202; JWH-204; JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-237; JWH-248; JWH-249; JWH-251; JWH-253; JWH-302; JWH-303; JWH-304; JWH-305; JWH-306; JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-316; Cannabipiperidiethanone; (d) Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline (WIN 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4); AM-630; AM-661; AM-2233; AM-1241; (e) Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Some trade or other names: JWH-307; JWH-030; JWH-031; JWH-145; JWH-146; JWH-147; JWH-150; JWH-156; JWH-242; JWH-243; JWH-244; JWH-245; JWH-246; JWH-292; JWH-293; JWH-308; JWH-309; JWH-346; JWH-348; JWH-363; JWH-364; JWH-365; JWH-367; JWH-368; JWH-369; JWH-370; JWH-371; JWH-373; JWH-392; (f) Naphthylmethylindenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. Some trade or other names: JWH-171; JWH-176; JWH-220; (g) Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not substituted in the cyclohexyl ring to any extent. Some trade or other names: 5-( 1 ,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47, 497 and homologues, which includes C8); cannabicyclohexanol; CP-55,490; CP-55,940; CP-56,667; (h) (6aR,10aR)-9-(hydroxymethyl )-6,6-dimethyl-3-(2-methyloctan-2-yl) 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names: HU-210; (i) 2,3-Dihydro-5-methyl-3-(4-m orpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenyl. Some trade or other names: WIN 55, 212-2; (j) Substituted Acetylindoles. Any compound containing a 3-acetyl indole structure substituted at the acetyl with a tetramethylcyclopropyl, adamantyl, or benzyl substituent whether or not further substituted in the tetramethylcyclopropyl, adamantyl, or benzyl substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent. Some trade and or names: (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144); (1-(5-fluoropentyl)indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11); (1-(2-morpholin-4-ylethyl)-1H-indol-3-yl)- (2,2,3,3-tetramethylcyclopropyl)methanone (A-796,260); 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole (AM-1248); 1-Pentyl-3-(1-adamantoyl)indole (AB-001 and JWH-018 adamantyl analog); AM-679; (k) Substituted Carboxamide Indole. Any compound containing a 3-carboxamide indole structure substituted at the carboxamide with a tetramethylcyclopropyl, naphthyl, or adamantyl substituent, whether or not further substituted in the tetramethylcyclopropyl, or adamantyl substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent. Some trade and other names: JWH-018 adamantyl carboxamide; STS-135; MN-18; 5-Fluoro-MN-18; (47) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI); (48) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); (49) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); (50) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); (51) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); (52) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2); (53) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); (54) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); (55) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); and (56) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); (57) Substituted phenethylamine. Any compound, unless specifically exempt, listed as a controlled substance in another schedule or an approved FDA drug, structurally derived from phenylethan-2-amine by substitution on the phenyl ring in any of the following ways, that is to say--by substitution with a fused methylenedioxy, fused furan, or fused tetrahydrofuran ring system; by substitution with two alkoxy groups; by substitution with one alkoxy and either one fused furan, tetrahydrofuran, or tetrahydropyran ring system; by substitution with two fused ring systems from any combination of the furan, tetrahydrofuran, or tetrahydropyran ring systems; whether or not the compound is further modified in any of the following ways: (a) By substitution on the phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl, alkoxy, or alkylthio groups; (b) By substitution on the 2-position by any alkyl groups; or (c) By substitution on the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, methoxybenzyl, or hydroxybenzyl groups. Some trade and other names: 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine (2C-T or 4-methylthio-2,5-dimethoxyphenethylamine); 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine (DOI or 2, 5-Dimethoxy-4-iodoamphetamine); 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB or 2,5-Dimethoxy-4-bromoamphetamine); 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine (DOC or 2,5-Dimethoxy-4-chloroamphetamine); 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-B-NBOMe; 25B-NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine); 2-4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-I-NBOMe; 25I-NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine); N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxypheny (Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-methoxybenzyl)phenethylamine); 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-C-NBOMe; 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine); 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine (2CB-5-hemiFLY); 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-FLY); 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-yl)ethanamine (2C-B-butterFLY); N-(2-Methoxybenzyl)-1- (8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b.]difuran-4-yl)-2-aminoethane (2C-B-FLY-NBOMe); 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (bromo-benzodifuranyl-isopropylamine or bromo-dragonFLY); N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine (2C-I-NBOH or 25I-NBOH); 5-(2-Aminoprpyl)benzofuran (5-APB); 6-(2-Aminopropyl)benzofuran (6- APB); 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB); 6-(2-Aminopropyl)-2,3,-dihydrobenzofuran (6-APDB); (58) Substituted tryptamines. Any compound, unless specifically exempt, listed as a controlled substance in another schedule or an approved FDA drug, structurally derived from 2-(1H-indol-3-yl)ethanamine (i.e, tryptamine) by mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom in a cyclic structure whether or not the compound is further substituted at the alpha-position with an alkyl group or whether or not further substituted on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups. Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin); 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DIPT); 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT); (59) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB-13); (60) N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide (AKB 48); (61) 1-(4-Fluorophenyl)piperazine (pFPP); (62) 1-(3-Chlorophenyl)piperazine (mCPP); (63) 1-(4-Methoxyphenyl)piperazine (pMeOPP); (64) 1,4-Dibenzylpiperazine (DBP); (65) Isopentedrone; (66) Fluoromethamphetamine; (67) Fluoroamphetamine; (68) Fluorococaine; (69) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22); (70) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5 Fluoro-PB-22); (71) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA); (72) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5 Fluoro-AB-PINACA); (73) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA); (74) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADB-PINACA (ADBICA)); (75) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5 Fluoro-ADB-PINACA (5 Fluoro-ADBICA)); (76) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA). Section 2. That \u00a7 34-20B-20 be amended to read as follows: 34-20B-20. Any material, compound, mixture, or preparation is included in Schedule III which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system: (1) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules; (2) Chloral betaine; (3) Chloral hydrate; (4) Chlorhexadol; (5) Lysergic acid; (6) Lysergic acid amide; (7) Methyprylon; (8) Sulfondiethylmethane; (9) Sulfonethylmethane; (10) Sulfonmethane; (11) Amobarbital, pentobarbital, and secobarbital in suppository dosage form; (12) Gamma hydroxy butyrate; (13) Dronabinol; (14) Buprenorphine; (15) Embutramide; (16) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile], including its salts, isomers, and salts of isomers. Section 3. Whereas, this Act is necessary for the immediate preservation of the public peace, health, or safety, an emergency is hereby declared to exist, and this Act shall be in full force and effect from and after its passage and approval."}, {"bill_id": 5538, "bill_version_id": 29803, "bill_version": "Enrolled", "bill_version_date": "2014-02-05T08:49:16.923-06:00", "bill_text": ""}], "amendments": [], "fiscal_notes": [], "action_log": [{"bill_id": 5538, "action_date": "2014-01-14T12:00:00-06:00", "document_id": 28475, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/28475.pdf", "status_text": "First read in House and referred to", "journal_page": 20, "committee_id_action": 231, "committee_id_assigned": 220, "result": "N", "vote": {}}, {"bill_id": 5538, "action_date": "2014-01-21T07:45:00-06:00", "document_id": 28525, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/28525.pdf", "status_text": "Scheduled for hearing", "journal_page": 0, "committee_id_action": 220, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 5538, "action_date": "2014-01-21T07:45:00-06:00", "document_id": 28654, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/28654.pdf", "status_text": "Do Pass", "journal_page": 55, "committee_id_action": 220, "committee_id_assigned": null, "result": "P", "vote": {"vote_id": 15061, "president_vote": null, "Yea": [525, 519, 481, 501, 479, 845, 430, 503, 510, 478], "Excused": [464, 520, 476]}}, {"bill_id": 5538, "action_date": "2014-01-22T14:00:00-06:00", "document_id": 28792, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/28792.pdf", "status_text": "Do Pass", "journal_page": 72, "committee_id_action": 231, "committee_id_assigned": null, "result": "P", "vote": {"vote_id": 15122, "president_vote": null, "Yea": [528, 527, 453, 522, 525, 433, 467, 524, 456, 489, 517, 519, 505, 449, 431, 455, 425, 504, 481, 509, 503, 477, 501, 520, 479, 457, 454, 523, 458, 451, 466, 845, 499, 442, 507, 478, 487, 423, 439, 500, 502, 497, 515, 511, 512, 463, 518, 484, 462, 485, 514, 459, 464, 510, 450, 506, 430, 513, 468, 498, 461, 516, 508, 480, 460, 448, 441], "Nay": [496, 521], "Excused": [476]}}, {"bill_id": 5538, "action_date": "2014-01-23T14:00:00-06:00", "document_id": 28899, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/28899.pdf", "status_text": "First read in Senate and referred to", "journal_page": 98, "committee_id_action": 229, "committee_id_assigned": 209, "result": "N", "vote": {}}, {"bill_id": 5538, "action_date": "2014-01-29T10:00:00-06:00", "document_id": 28981, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/28981.pdf", "status_text": "Scheduled for hearing", "journal_page": 0, "committee_id_action": 209, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 5538, "action_date": "2014-01-29T10:00:00-06:00", "document_id": 29275, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/29275.pdf", "status_text": "Do Pass", "journal_page": 142, "committee_id_action": 209, "committee_id_assigned": null, "result": "P", "vote": {"vote_id": 15355, "president_vote": null, "Yea": [437, 846, 465, 429, 475, 493, 432]}}, {"bill_id": 5538, "action_date": "2014-01-29T10:00:00-06:00", "document_id": 29275, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/29275.pdf", "status_text": "Placed on consent", "journal_page": 0, "committee_id_action": 209, "committee_id_assigned": null, "result": "P", "vote": {}}, {"bill_id": 5538, "action_date": "2014-01-30T14:00:00-06:00", "document_id": 29451, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/29451.pdf", "status_text": "Removed from Consent Calendar", "journal_page": 173, "committee_id_action": 229, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 5538, "action_date": "2014-01-31T13:00:00-06:00", "document_id": 29580, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/29580.pdf", "status_text": "Deferred to another day", "journal_page": 188, "committee_id_action": 229, "committee_id_assigned": null, "result": "P", "vote": {}}, {"bill_id": 5538, "action_date": "2014-02-04T14:00:00-06:00", "document_id": 29778, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/29778.pdf", "status_text": "Do Pass", "journal_page": 213, "committee_id_action": 229, "committee_id_assigned": null, "result": "P", "vote": {"vote_id": 15577, "president_vote": null, "Yea": [469, 437, 444, 473, 846, 495, 447, 472, 470, 432, 465, 847, 483, 443, 429, 452, 436, 438, 526, 424, 492, 491, 428, 475, 435, 440, 493, 849, 474, 426, 494, 434, 490, 486], "Excused": [446]}}, {"bill_id": 5538, "action_date": "2014-02-05T14:00:00-06:00", "document_id": 29859, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/29859.pdf", "status_text": "Signed by the Speaker", "journal_page": 302, "committee_id_action": 231, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 5538, "action_date": "2014-02-06T14:00:00-06:00", "document_id": 29947, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/29947.pdf", "status_text": "Signed by the President", "journal_page": 248, "committee_id_action": 229, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 5538, "action_date": "2014-02-07T13:00:00-06:00", "document_id": 30024, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/30024.pdf", "status_text": "Delivered to the Governor", "journal_page": 341, "committee_id_action": 231, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 5538, "action_date": "2014-02-10T14:00:00-06:00", "document_id": 30114, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/30114.pdf", "status_text": "Signed by the Governor", "journal_page": 346, "committee_id_action": 231, "committee_id_assigned": null, "result": "N", "vote": {}}], "session_law": 5653, "rss_feed": "https://sdlegislature.gov/api/Bills/RSS/5538"}